While he cautions that equities may face pressure and deliver subpar returns in the near term, he believes the current environment presents a rare window for bargain hunters to accumulate high-quality stocks at reasonable valuations.
Dr Reddy’s Labs Q4 Results: Cons PAT jumps 22% to Rs 1,594 crore; Rs 8 per share dividend announced
Dr Reddy’s Labs Q4 Results: Dr Reddy’s Laboratories on Friday reported a consolidated net profit growth of 22% to Rs 1,594 crore in Q4FY25 versus